A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
A phase 3 trial testing SHR-1501 in bladder & urothelial cancer, now recruiting.
Overview
A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC is a phase 3 interventional study registered as NCT07726992, led by Suzhou Suncadia Biopharmaceuticals, and recruiting when checked on 2026-09-11. Official title: A Multicenter, Randomised, Double-blind Phase III Study of Intravesical SHR-1501 Combined With Bacillus Calmette Guerin (BCG) Versus Placebo Combined With BCG In Patients With High-risk BCG-naive Papillary-Only Non-muscle-invasive Bladder Cancer (NMIBC). Planned enrolment is 750 participants (estimated). The study started in 2026-08-25 and primary completion is expected in 2029-12. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Shares SHR-1501, Jiangsu Hengrui Pharmaceuticals, Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.
- TrialA Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
Shares Jiangsu Hengrui Pharmaceuticals and the tag ctgov-ingest.